Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 1/20 | 1.00 |
| ▸ | BRD4 | O60885 | 13/20 | 0.78 |
| ▸ | NT5C2 | P49902 | 2/20 | 0.71 |
| ▸ | NT5E | P21589 | 1/20 | 0.71 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.61 |
| ▸ | TOP2A | P11388 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23124 | 0.82 | BRD4 (1.00) | CREBBPBRD4NT5C2NT5ETOP2A | |
| SCHEMBL29514799 | 0.82 | BRD4 (1.00) | CREBBPBRD4NT5C2NT5ETOP2A | |
| SCHEMBL6463477 | 0.82 | BRD4 (0.92) | CREBBPBRD4NT5C2NT5ETOP2A | |
| SCHEMBL8381776 | 0.81 | BRD4 (0.97) | CREBBPBRD4NT5C2NT5ETOP2A | |
| SCHEMBL9230081 | 0.80 | BRD4 (1.00) | CREBBPBRD4NT5C2NT5EMKNK1 | |
| SCHEMBL21401478 | 0.74 | BRD4 (1.00) | CREBBPBRD4NT5C2NT5E | |
| SCHEMBL10644711 | 0.73 | BRD4 (0.68) | CREBBPBRD4NT5C2NT5EMKNK1 | |
| SCHEMBL536913 | 0.72 | BRAF (0.72) | CREBBPBRD4NT5C2NT5ENPC1 | |
| SCHEMBL29475418 | 0.72 | BRAF (0.72) | CREBBPBRD4NT5C2NT5ENPC1 | |
| SCHEMBL1898392 | 0.71 | BRD4 (0.64) | CREBBPBRD4NT5C2NT5ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-02-16 | — | — | US | disclosed |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-08-05 | — | — | US | disclosed |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ATXN2L, ATXN2, ATXN10 | CREBBP 641/4885BRD4 983/4885NT5C2 1539/4885 |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | CREBBP 132/4885BRD4 679/4885NT5C2 713/4885 |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | CREBBP 132/4885BRD4 679/4885NT5C2 713/4885 |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CYFIP2, TPX2, ATXN2 | CREBBP 1345/4885BRD4 2609/4885NT5C2 629/4885 |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, F13B, GRN | CREBBP 137/4885BRD4 1635/4885NT5C2 1230/4885 |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, UBQLN2, UBTF | CREBBP 273/4885BRD4 392/4885NT5C2 1784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.